Recombinant Mouse ALCAM His-tag Protein, CF

When Recombinant Mouse ALCAM/CD166 is immobilized at 1 μg/mL, Recombinant Biotinylated Human CD6 Fc Chimera binds with an ED50 of 6-36 ng/mL.

2 μg/lane of Recombinant Mouse ALCAM/CD166 was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 81-95 kDa.

• Reactivity: Mu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Mouse ALCAM His-tag Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Mouse ALCAM/CD166 is coated at 1 µg/mL, Recombinant Biotinylated Human CD6 Fc Chimera binds with an ED₅₀ of 6‑36 ng/mL.
• Source: Mouse myeloma cell line, NS0-derived mouse ALCAM/CD166 protein
  Trp28-Lys527, with a C-terminal 6-His tag
• Accession #: AAC06342
• N-terminal Sequence: Trp28
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 57 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 81-95 kDa, reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, ≤ -20 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, ≤ -20 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Mouse ALCAM His-tag Protein, CF

• activated leucocyte cell adhesion molecule
• activated leukocyte cell adhesion moleculeFLJ38514
• ALCAM
• CD166 antigen
• CD166
• MEMDMGC71733

Background

ALCAM (activated leukocyte cell adhesion molecule), designated CD166 and also called MEMD and SC-1/DM-GRASP/BEN in the chicken, is a 100-110 kDa type I transmembrane glycoprotein and a member of the Ig CAM family within the immunoglobulin superfamily (1). ALCAM is expressed on thymic epithelium, microvascular endothelium, activated lymphocytes and monocytes, and monocyte ­derived dendritic cells (1, 2). Mouse ALCAM cDNA encodes 583 amino acid (aa), including signal peptide (27 aa), extracellular domain (ECD, 500 aa) with two V-type and three C2-type Ig-like domains, transmembrane (22 aa) and cytoplasmic (34 aa) domains (1). Mouse ALCAM ECD shares 98%, 93%, and 92% aa sequence identity with rat, human/porcine and bovine/equine ALCAM, respectively. A secreted isoform in endothelial cells that is truncated at aa 133 (sALCAM) antagonizes full‑length ALCAM (3, 4). ALCAM mediates low affinity adhesion with itself or the cysteine-rich scavenger receptor CD6 to regulate T cell development, immunological synapses (IS), and cell migration through endothelial junctions (1-11). ALCAM on thymic epithelia mediates adhesion to CD6 on CD4⁺CD8⁺ T cells (6). Adhesion of ALCAM-expressing antigen presenting cells and CD6-expressing T cells stabilizes the early IS, while later it enhances CD3 effects on T cell proliferation, CD25 expression, and Th1 commitment (2, 7, 8). High ALCAM expression at the blood brain barrier in active multiple sclerosis, and its mouse model (EAE), promotes leukocyte migration to the brain (8, 9). High ALCAM expression on melanoma cell lines appears to be pro-metastatic, but anti-metastatic activity has been reported in breast cancer (3, 10, 11). ALCAM may influence expression or adhesion of the neuronal adhesion molecule NCAM-L1, both in the developing retina and invasive melanoma (3, 12). It may also play a role in stabilizing cell-cell interaction among lymphatic endothelial cells (LECs) and affecting the organization and function of the lymphatic vessel (LV) network (13).

1. Bowen, M.A. et al. (1995) J. Exp. Med. 181:2213.
2. Zimmerman, A.W. et al. (2006) Blood 107:3212.
3. van Kilsdonk, J.W.J. et al. (2008) Cancer Res. 68:3671.
4. Ikeda, K. and T. Quertermous (2004) J. Biol. Chem. 279:55315.
5. van Kempen, L.C. et al. (2001) J. Biol. Chem. 276:25783.
6. Castro, M.A.A. et al. (2007) J. Immunol. 178:4351.
7. Nair, P. et al. (2010) Clin. Exp. Immunol. 162:116.
8. Masedunskas, A. et al. (2006) FEBS Lett. 580:2637.
9. Cayrol, R. et al. (2008) Nat. Immunol. 9:137.
10. Degen, W.G. et al. (1998) Am. J. Pathol. 152:805.
11. King, J.A. et al. (2010) Mol. Cancer 9:266.
12. Buhusi, M. et al. (2009) J. Neurosci. 29:15630.
13. Iolyeva M. et al. (2013) FASEB J. 27:978.

Bioinformatics

• Uniprot:
  • AAC06342()